• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Biomarker Technologies Market

    ID: MRFR/LS/4692-HCR
    100 Pages
    Rahul Gotadki
    September 2025

    Biomarker Technologies Market Research Report Information By Product (Consumables, Instruments), By Profiling Technology (PCR, Imaging Technology, NGS), By Application (Cancer, Infectious Disease), By Research Area (Genomics, Proteomics), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Biomarker Technologies Market Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Biomarker Technologies Market Summary

    The Global Biomarker Technologies Market is projected to grow significantly from 37.6 USD Billion in 2024 to 87.68 USD Billion by 2035.

    Key Market Trends & Highlights

    Biomarker Technologies Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate of 8.01 percent from 2025 to 2034.
    • By 2035, the market valuation is anticipated to reach 87.7 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 37.6 USD Billion, reflecting a strong foundation for future expansion.
    • Growing adoption of biomarker technologies due to increasing demand for personalized medicine is a major market driver.

    Market Size & Forecast

    2024 Market Size 37.56 (USD Billion)
    2035 Market Size 87.68 (USD Billion)
    CAGR (2025-2035) 8.01%

    Major Players

    Abbott Laboratories, Agilent Technologies, Thermo Fisher Scientific, Roche, Waters Corporation, Danaher Corporation, Shimadzu Corporation, Siemens Healthcare

    Biomarker Technologies Market Trends

    Growing diagnostic applications of biomarkers are driving the market growth.

    Biomarkers are prominently used in companion diagnostics, personalized medicine, disease risk assessment, and drug discovery and development. The rising adoption of biomarkers in disease diagnostics is one of the major factors expected to drive the market CAGR growth during 2019-2026. Biomarkers play a prominent role in personalized medicine, including various applications such as diagnosis, prognosis, and targeted therapies for numerous disease conditions. Personalized medicine has gained acknowledgment due to limitations in traditional disease diagnosis and treatment procedures. Patients with cancer and immunological disorders are inclined toward tailored treatment options based on clinical and genetic features.

    The rising demand for personalized medicine is one of the major factors driving the demand for biomarkers, fueling the market's growth.

    The increasing integration of biomarker technologies into clinical practice is poised to enhance personalized medicine, thereby improving patient outcomes and streamlining therapeutic development.

    National Institutes of Health (NIH)

    Biomarker Technologies Market Drivers

    Market Growth Projections

    The Global Biomarker Technologies Market Industry is projected to experience substantial growth over the coming years. With a market value of 37.6 USD Billion in 2024, it is anticipated to expand at a CAGR of 8.01% from 2025 to 2035, potentially reaching 87.7 USD Billion by 2035. This growth trajectory reflects the increasing demand for biomarker technologies across various applications, including diagnostics, drug development, and personalized medicine. The convergence of technological advancements, rising chronic disease prevalence, and regulatory support further underscores the market's potential for expansion.

    Increased Investment in R&D

    The Global Biomarker Technologies Market Industry benefits from heightened investment in research and development across various sectors, including pharmaceuticals and biotechnology. Governments and private entities are allocating substantial funds to explore biomarker applications in drug discovery and development. For instance, the National Institutes of Health has prioritized biomarker research, recognizing its potential to enhance therapeutic efficacy and safety. This influx of funding fosters innovation and accelerates the development of novel biomarker technologies. Consequently, the market is poised for significant growth, with projections indicating a rise to 37.6 USD Billion in 2024.

    Advancements in Genomic Technologies

    Technological advancements in genomics significantly influence the Global Biomarker Technologies Market Industry. Innovations such as next-generation sequencing and CRISPR gene editing enhance the ability to identify and validate biomarkers. These technologies facilitate the discovery of novel biomarkers that can lead to breakthroughs in diagnostics and therapeutics. For example, the integration of genomic data into clinical practice has improved patient stratification in oncology. As the market evolves, it is projected to grow at a CAGR of 8.01% from 2025 to 2035, potentially reaching 87.7 USD Billion by 2035, underscoring the importance of genomic advancements.

    Rising Prevalence of Chronic Diseases

    The increasing incidence of chronic diseases globally drives the Global Biomarker Technologies Market Industry. Conditions such as cancer, diabetes, and cardiovascular diseases necessitate advanced diagnostic tools for early detection and personalized treatment. For instance, the World Health Organization indicates that cancer cases are projected to rise by 70 percent over the next two decades. This surge in chronic diseases creates a substantial demand for biomarker technologies, which are essential for developing targeted therapies. The market is expected to reach 37.6 USD Billion in 2024, reflecting the urgent need for innovative solutions in disease management.

    Growing Demand for Personalized Medicine

    The shift towards personalized medicine is a pivotal driver for the Global Biomarker Technologies Market Industry. As healthcare moves away from one-size-fits-all approaches, biomarkers play a crucial role in tailoring treatments to individual patient profiles. This trend is evident in oncology, where biomarkers guide treatment decisions based on genetic and molecular characteristics. The increasing acceptance of personalized medicine is likely to propel market growth, as healthcare providers seek to improve patient outcomes. The market is expected to expand significantly, potentially reaching 87.7 USD Billion by 2035, reflecting the growing emphasis on personalized therapeutic strategies.

    Regulatory Support for Biomarker Development

    Regulatory agencies worldwide are increasingly supporting the development and validation of biomarkers, which positively impacts the Global Biomarker Technologies Market Industry. Initiatives aimed at streamlining the approval process for biomarker-based diagnostics and therapeutics encourage innovation and investment. For example, the U.S. Food and Drug Administration has established guidelines to facilitate the use of biomarkers in drug development. This regulatory support not only accelerates the introduction of new biomarker technologies but also enhances their credibility in clinical settings. As a result, the market is anticipated to grow, reaching 37.6 USD Billion in 2024.

    Market Segment Insights

    Biomarker Technologies Product Insights

    Based on Product, the Biomarker Technologies market segmentation includes consumables and instruments. The consumables segment dominated the market because consumables are a crucial part of biomarker testing and are required for performing various technologies. Therefore, this leads to the growth of this market. On the other side, the instruments segment is the fastest growing segment during the forecast period, owing to the technological advancements which have rendered these instruments more precise and quick. Moreover, the rise in the adoption of biomarker technologies across various fields of science contributes to the market growth of biomarker technologies.

    Figure 1 Biomarker Technologies Market, by Product, 2022 & 2032 (USD billion)

    Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

    Biomarker Technologies Profiling Technology Insights

    Based on Profiling Technology, the Biomarker Technologies market segmentation includes PCR, imaging technology, and NGS. The PCR segment dominated the marketdue to its ability to amplify DNA and RNA samples and detect genetic mutations. PCR technology is widely used in medical and biological research, diagnostic laboratories, and forensic labs.

    Biomarker Technologies Application Insights

    Based on Application, the Biomarker Technologies market segmentation includes cancer and infectious disease. The cancer segment dominated the market; the segment's growth is due to an increase in demand for rapid & accurate diagnostic tools and a rise in the incidence of cancer biomarker.Hence, using biomarkers to detect cancer, estimate prognosis, monitor response to the treatment, and check for the development of resistance to treatment is crucial in disease management. Furthermore, an increase in the demand for personalized medicines, coupled with growing collaborations between pharmaceutical and diagnostic companies, is anticipated to drive the segment.

    Biomarker Technologies Research Area Insights

    The Biomarker Technologies market segmentation, based on research areas, includes genomics and proteomics. The genomics segment dominated the market because it involves the identification, quantification, and analysis of proteins, which play a crucial role in the diagnosis, treatment, and prevention of various diseases. Proteomics technologies, such as mass spectrometry and protein microarrays, are widely used in drug discovery and development, personalized medicine, and clinical diagnostics.

    Get more detailed insights about Biomarker Technologies Market Research Report – Forecast to 2034

    Regional Insights

    By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American biomarker technologies market will dominate due to the high disease burden, increased consumer awareness about biomarkers, supportive government initiatives, technological advancements, and healthcare infrastructure improvements that will boost the Region's market growth.

    Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

    Figure 2 BIOMARKER TECHNOLOGIES MARKET SHARE BY REGION 2022 (%)

    Biomarker Technologies Market

    Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

    Europe Biomarker Technologies market accounts for the second-largest market share due to the increased prevalence of chronic diseases, rising healthcare expenditure, and rising standard of living. Further, the German Biomarker Technologies market held the largest market share, and the UK Biomarker Technologies market was the fastest-growing market in the European Region.

    The Asia-Pacific Biomarker Technologies Market is expected to grow at the fastest CAGR from 2024 to 2032. This is due toa surge in funding for biomarkers discovery, the high prevalence of cancer, rising research initiatives, and the low cost of clinical trials in developing nations are expected to support regional growth. Moreover, China’s Biomarker Technologies market held the largest market share, and the Indian Biomarker Technologies market was the fastest-growing market in the Asia-Pacific region.

    Key Players and Competitive Insights

    Leading market players are investing heavily in research and development to expand their product lines, which will help the biomarker technologies market grow even more. Market participants are also undertaking various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. The biomarker technologies industry must offer cost-effective items to expand and survive in a more competitive and rising market climate.

    Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the Biomarker Technologies industry to benefit clients and increase the market sector. The Biomarker Technologies industry has offered some of the most significant medical advantages in recent years. Major Biomarker Technologies market players include Abbott Laboratories, Agilent Technologies, Thermo Fisher Scientific, Roche, Waters Corporation, Danaher Corporation, Shimadzu Corporation, Danaher Corporation Siemens Healthcare, and others, are attempting to increase market demand by investing in research and development operations.

    QIAGEN N.V., the corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. Furthermore, European, American, and Asian regional headquarters are located in respectively Hilden, Germany, Maryland, United States, and Shanghai, China.QIAGEN N.V. announced the launch of its FDA-approved tissue companion diagnostic to identify the KRAS G12C mutation in NSCLC tumors; this will help them expand their precision medicine portfolio for Lung Cancer.

      • Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel.F. Hoffmann-La Roche Ltd announced a series of five new uses for their cardiac biomarkers using the Elecsys technology. These biomarkers have been proven successful in supporting cardiovascular disease management.
    • Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel.F. Hoffmann-La Roche Ltd announced a series of five new uses for their cardiac biomarkers using the Elecsys technology. These biomarkers have been proven successful in supporting cardiovascular disease management.

    Key Companies in the Biomarker Technologies Market market include

    Industry Developments

    • Q2 2024: Roche launches new high-throughput biomarker assay platform for oncology diagnostics Roche announced the commercial launch of its new Elecsys NGS-based biomarker assay platform, designed to accelerate and expand precision oncology diagnostics in clinical laboratories.
    • Q2 2024: Thermo Fisher Scientific Acquires Olink Holding AB, Expanding Proteomics and Biomarker Discovery Portfolio Thermo Fisher Scientific completed its acquisition of Olink Holding AB, a leader in proteomics and biomarker discovery, strengthening its position in high-throughput protein biomarker analysis.
    • Q3 2024: Quanterix Launches Simoa Neurology Biomarker Panel for Early Alzheimer’s Detection Quanterix introduced a new Simoa-based neurology biomarker panel, enabling earlier and more accurate detection of Alzheimer’s disease through blood-based assays.
    • Q3 2024: Grail and AstraZeneca Announce Partnership to Develop Multi-Cancer Early Detection Biomarker Tests Grail and AstraZeneca entered a strategic partnership to co-develop and commercialize multi-cancer early detection tests using advanced biomarker technologies.
    • Q2 2024: Bio-Techne Opens New Biomarker Manufacturing Facility in Minnesota Bio-Techne inaugurated a new state-of-the-art manufacturing facility dedicated to the production of biomarker reagents and kits, aiming to meet growing global demand.
    • Q1 2024: Guardant Health Receives FDA Approval for Blood-Based Colorectal Cancer Biomarker Test Guardant Health secured FDA approval for its blood-based colorectal cancer screening test, marking a significant regulatory milestone in non-invasive cancer diagnostics.
    • Q2 2025: Siemens Healthineers Acquires Biomarker Analytics Startup DeepBio for $350 Million Siemens Healthineers acquired DeepBio, a South Korean biomarker analytics company, to enhance its AI-driven pathology and biomarker discovery capabilities.
    • Q1 2025: Abbott Launches Digital Biomarker Platform for Remote Cardiac Monitoring Abbott introduced a new digital biomarker platform that enables remote monitoring of cardiac patients, integrating wearable sensors and AI analytics.
    • Q2 2025: Biocept Secures $25 Million Funding to Advance Liquid Biopsy Biomarker Technologies Biocept raised $25 million in a new funding round to accelerate the development and commercialization of its liquid biopsy biomarker platforms for cancer diagnostics.
    • Q3 2024: Illumina and Genomics England Partner to Develop Genomic Biomarker Panels for Rare Disease Diagnosis Illumina and Genomics England announced a collaboration to create new genomic biomarker panels aimed at improving rare disease diagnosis and patient outcomes.
    • Q1 2025: Exact Sciences Appoints New Chief Scientific Officer to Lead Biomarker Innovation Exact Sciences named Dr. Maria Lopez as Chief Scientific Officer, tasking her with driving the company’s biomarker research and development strategy.
    • Q2 2024: Bristol Myers Squibb and Tempus Announce Collaboration on AI-Driven Biomarker Discovery for Immuno-Oncology Bristol Myers Squibb and Tempus launched a multi-year collaboration to leverage AI and real-world data for the discovery and validation of novel immuno-oncology biomarkers.

    Future Outlook

    Biomarker Technologies Market Future Outlook

    The Biomarker Technologies Market is projected to grow at 8.01% CAGR from 2024 to 2034, driven by advancements in personalized medicine, increased R&D investments, and rising demand for early disease detection.

    New opportunities lie in:

    • Develop AI-driven biomarker discovery platforms to enhance diagnostic accuracy.
    • Invest in partnerships with biotech firms for innovative biomarker applications.
    • Expand into emerging markets with tailored biomarker solutions for local health challenges.

    By 2035, the Biomarker Technologies Market is expected to be robust, reflecting substantial growth and innovation.

    Market Segmentation

    Biomarker Technologies Regional Outlook

    North America
    • US
    • Canada

    Biomarker technologies Products Outlook

    • Consumables
    • Instruments

    Biomarker technologies Application Outlook

    • Cancer
    • Infectious Disease

    Biomarker Technologies Research Area Outlook

    • Genomics
    • Proteomics

    Biomarker technologies Profiling Technology Outlook

    • PCR
    • Imaging Technology
    • NGS

    Report Scope

    Report Attribute/Metric Details
    Market Size 2024   37.56 (USD Billion)
    Market Size 2025   40.57 (USD Billion)
    Market Size 2034   81.18 (USD Billion)
    Compound Annual Growth Rate (CAGR)    8.01 % (2025 - 2034)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2024
    Market Forecast Period 2025 - 2034
    Historical Data 2020 - 2024
    Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
    Segments Covered Product, Profiling Technology,Application, Research Area, and Region
    Geographies Covered North America, Europe, AsiaPacific, and the Rest of the World
    Countries Covered The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies Profiled Abbott Laboratories, Agilent Technologies, Thermo Fisher Scientific, Roche, Waters Corporation, Danaher Corporation, Shimadzu Corporation, Danaher Corporation, Siemens Healthcare
    Key Market Opportunities Increasing research & development investments by industry players and governmental initiatives supporting research
    Key Market Dynamics Increasing prevalence of chronic diseases Rising healthcare expenditure and rise in the standard of living

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    How much is the Biomarker Technologies market?

    The Biomarker Technologies market size was valued at USD 34.39 Billion in 2023.

    What is the growth rate of the Biomarker Technologies market?

    The market is projected to grow at a CAGR of 8.01%during the forecast period, 2025-2034.

    Which Region held the largest market share in the Biomarker Technologies market?

    North America had the largest share of the market

    Who are the key players in the Biomarker Technologies market?

    The key players in the market areAbbott Laboratories, Agilent Technologies, Thermo Fisher Scientific, Roche, Waters Corporation, Danaher Corporation, Shimadzu Corporation, Danaher Corporation, and Siemens Healthcare.

    Which Product led the Biomarker Technologies market?

    The consumables category dominated the market in 2023.

    Which Application had the largest market share in the Biomarker Technologies market?

    The cancer had the largest share in the market.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials